Efficacy and Safety of Qishen Yiqi Dripping Pill for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis

Abstract

Background: The number of heart failure with preserved ejection fraction (HFpEF) patients is increasing year by year, yet all western medicines currently used for heart failure have been shown to be ineffective for HFpEF. Qishen Yiqi Dripping Pill is one of the commonly drugs for the treatment of heart failure in China. In recent years, some clinical studies found that it has curative effect on HFpEF.Objective: To evaluate the efficacy and safety of Qishen Yiqi Dripping Pill in treatment of HFpEF.Methods: Databases including CNKI, Wanfang, VIP, CBM, PubMed, Web of Science, The Cochrane Library and EMbase were searched from their inception to May 2020 to screen relevant randomized controlled trials. The “risk of bias” evaluation tool in the Cochrane Handbook was used to evaluate the quality of the included studies. RevMan 5.3 software was used for meta-analysis.Results: Eight studies meeting the criteria were included, with a total of 895 patients. The results of meta-analysis showed that compared with western medicine alone, combination of western medicine and Qishen Yiqi Dripping Pill can further increase the quotient of early diastolic mitral inflow velocity and late diastolic mitral inflow velocity (E/A) in patients with HFpEF [mean difference (MD) = 0.20, 95% CI (0.14, 0.26), p < 0.000 01], decrease the quotient of early diastolic mitral inflow velocity and mitral annular tissue velocity (E/e′) [MD = −2.50, 95% CI (−3.18, −1.82), p < 0.000 01], decrease brain natriuretic peptide (BNP) [MD = −151.83, 95% CI (−245.78, −57.89), p = 0.002], increase cardiac function improvement rate [relative risk (RR) = 1.30, 95% CI (1.11, 1.52), p = 0.001], and increase six-minutes walking distance (6-MWD) [MD = 64.75, 95% CI (22.65, 106.85), p = 0.003]. Four studies reported the occurrence of adverse reactions, among which three studies reported no adverse reactions and one study reported three patients with mild adverse reactions in the intervention group.Conclusion: Current evidence suggests that Qishen Yiqi Dripping Pill may be effective in the treatment of HFpEF. However, due to the low quality of the included studies, lack of placebo control, large heterogeneity among different studies, and great possibility of publication bias, the results of our review should be evaluated with more prudence, more high-quality clinical studies are needed to verify the conclusion in the future. In addition, the safety of Qishen Yiqi Dripping Pill remains uncertain, further assessment is required in the future.

Efficacy of Chinese traditional patent medicines for heart failure with preserved ejection fraction: a Bayesian network meta-analysis of 64 randomized controlled trials

“…There have been several systematic quantitative evaluation studies of CTPMs for the treatment of HFPEF, and these CTPMs are approved by the NMPA of China. Wang et al ( 9 ) conducted a systematic review that demonstrated the improvement in NYHA efficiency, E/A, 6MWT, and the reduction in BNP when using QSYQDP + CWM compared to CWM alone. Cao et al ( 11 ) and Ge et al ( 87 ) found that QLQXC + CWM improved clinical efficiency, E/A, 6MWT and reduced BNP, NT-proBNP and Minnesota living with heart failure questionnaire scores compared to CWM.…”

Prognosis value of EAS index in patients with obstructive coronary artery disease

“…TDI measurements including systolic velocity (s’), early (e’), and late (a’) diastolic velocities were recorded at the septal mitral annulus in apical 4-chamber view ( 13 ). The transmitral to mitral annular early diastolic velocity ratio (E/e’) was calculated ( 14 , 15 ). We also defined the ratio of early and late diastolic velocities as the e’/a’ ratio ( 16 ).…”

New approach to heart failure: Integrated traditional Chinese with Western medicine

“…A recent meta‐analysis showed that, compared to WM alone, a combination of WM and Qishen Yiqi dripping pills can further increase early to late diastolic transmitral flow velocity (E/A) (mean difference = 0.20, p < 0.00001), decrease early diastolic transmitral flow velocity to early diastolic mitral annular tissue velocity (E/e') (mean difference = −2.50, p < 0.00001), as well as ameliorate BNP levels and 6MWT distance ( p < 0.005). Nonetheless, additional well‐designed, large‐scale clinical studies are required to confirm these findings [39]. Several other RCTs have indicated that Qishen Yiqi dripping pills can ameliorate inflammation and ventricular remodeling [40, 41], as well as contribute to reducing fasting blood glucose and glycated hemoglobin (HbA1c) levels in HF patients with diabetes mellitus [42].…”